CD69

Across TCGA pan-cancer cohorts, CD69 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CD69 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CD69 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CD69 expression acts as an unfavorable survival marker, although some lineages such as LUAD and GBM show a favorable association.

LUAD, GBM, and LSCC are the cancer types where CD69 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	II,III,IV	0.799	0.319	.030	4	view →
GBM	DFS	Median	All	0.851	0.303	.017	3	view →
LSCC	DFS	Median	II,III,IV	0.888	0.200	.024	2	view →
PDAC	OS	Tertile	II,III,IV	0.746	0.132	.027	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CD69–LUAD (DFS)

Open the LUAD breakdown →